glp-1 drugs mechanism of action and the kidney: from physiology to pharmacology and outcomes in diabetes Glucagon-like peptide-1 - Wikipedia

The US Food and Drug Administration (FDA) considered the world standard on drug and vaccine approval approved raloxifene for the prevention of invasive breast cancer

Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) are extensively prescribed to treat obesity and diabetes

These agonists are developed to maximize metabolic benefits and reduce side effects (126)

Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 177 randomized controlled trials with a median follow-up of 26 weeks

has received honoraria for consultancy from the Baim Institute for Clinical Research

Increasing attention has been directed toward the concept of a therapeutic window of opportunity, which frames early PsA as a transitional phase characterized by musculoskeletal symptoms such as arthralgia, dactylitis, and subclinical enthesitis in patients with PsO, often preceding clinically evident arthritis (12)